Literature DB >> 30371591

Rib Fractures Mimicking Bone Metastases in 18F-PSMA-1007 PET/CT for Prostate Cancer.

Emmanouil Panagiotidis1, Anna Paschali, Evanthia Giannoula, Vasiliki Chatzipavlidou.   

Abstract

Prostate-specific membrane antigen (PSMA) is a membrane glycoprotein that is overexpressed in prostate cancer cells. It is also expressed in other normal tissues and several other malignant and benign diseases. We present a case of a 69-year-old man with history of prostate adenocarcinoma who underwent F-PSMA-1007 PET/CT due to suspected biochemical recurrence. PET/CT showed F-PSMA-1007 uptake in healing rib fractures with no other pathologic findings. Clinicians reporting F-PSMA-1007 PET/CT should be aware of this potential pitfall, especially in nontypical trauma pattern (eg, solitary osseous lesion) mimicking bone metastases.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30371591     DOI： 10.1097/RLU.0000000000002354

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN： 0363-9762            Impact factor:   7.794


  8 in total

Review 1.  Looking for Drugs in All the Wrong Places: Use of GCPII Inhibitors Outside the Brain.

Authors:  James J Vornov; Diane Peters; Mike Nedelcovych; Kristen Hollinger; Rana Rais; Barbara S Slusher
Journal:  Neurochem Res       Date:  2019-11-20       Impact factor: 3.996

Review 2.  Update of PSMA Theranostics in Prostate Cancer: Current Applications and Future Trends.

Authors:  Chalermrat Kaewput; Sobhan Vinjamuri
Journal:  J Clin Med       Date:  2022-05-12       Impact factor: 4.964

3.  E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET.

Authors:  Francesco Ceci; Daniela E Oprea-Lager; Louise Emmett; Judit A Adam; Jamshed Bomanji; Johannes Czernin; Matthias Eiber; Uwe Haberkorn; Michael S Hofman; Thomas A Hope; Rakesh Kumar; Steven P Rowe; Sarah M Schwarzenboeck; Stefano Fanti; Ken Herrmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-19       Impact factor: 9.236

Review 4.  Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature.

Authors:  Henk B Luiting; Pim J van Leeuwen; Martijn B Busstra; Tessa Brabander; Henk G van der Poel; Maarten L Donswijk; André N Vis; Louise Emmett; Phillip D Stricker; Monique J Roobol
Journal:  BJU Int       Date:  2019-11-29       Impact factor: 5.588

5.  Added value of 68Ga-PSMA PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous 99mTc bone scintigraphy.

Authors:  Helle D Zacho; Søren Ravn; Ali Afshar-Oromieh; Joan Fledelius; June A Ejlersen; Lars J Petersen
Journal:  EJNMMI Res       Date:  2020-04-08       Impact factor: 3.138

6.  The performance of 18F-PSMA PET/CT in the detection of prostate cancer: a systematic review and meta-analysis.

Authors:  Zhi-Qiang Qin; Gao-Jian Pan; Zheng Xu; Hao Wang; Lu-Wei Xu; Rui-Peng Jia
Journal:  Asian J Androl       Date:  2022 Jul-Aug       Impact factor: 3.054

7.  The influence of digital PET/CT on diagnostic certainty and interrater reliability in [68Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer.

Authors:  Ian Alberts; Jan-Niklas Hünermund; Christos Sachpekidis; Clemens Mingels; Viktor Fech; Karl Peter Bohn; Axel Rominger; Ali Afshar-Oromieh
Journal:  Eur Radiol       Date:  2021-04-15       Impact factor: 5.315

8.  Duodenal Adenocarcinoma Mimicking Metastasis of Prostate Cancer on 18F-Prostate-Specific Membrane Antigen-1007 PET/CT.

Authors:  Fumihiko Soeda; Tadashi Watabe; Hiroki Kato; Motohide Uemura; Norio Nonomura
Journal:  Clin Nucl Med       Date:  2021-01       Impact factor: 10.782
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.